ACAD Historical PE Ratio Notes

— ACADIA Pharmaceuticals (ACAD) is a biopharmaceutical company focused on developing & commercializing therapies for central nervous system (CNS) disorders, such as Parkinson's disease psychosis & Rett syndrome. Their leading product, NUPLAZID®, addresses unmet needs in neuropsychiatric conditions, while their development pipeline targets rare & orphan neuropsychiatric & neurological syndromes. Understanding these fundamentals is crucial when reviewing ACAD's historical price-to-earnings (PE) ratio history. As a biotech firm with heavy R&D investments, ACAD often reported negative earnings in its early years, which makes the PE ratio either very high or not meaningful (“N/A”). Positive earnings—driven mainly by product approvals, increasing sales, & regulatory milestones—can dramatically change the PE, sometimes causing sudden drops if ACAD becomes profitable or spikes if earnings fall with additional spend. Thus historical PE trends for ACAD should be evaluated in the context of its product launches, regulatory news, or pipeline setbacks. Bear in mind, the biotech industry often assigns lofty valuations in anticipation of future profits, so historical PE ratios must be interpreted alongside clinical & commercial progress unique to ACAD's business model.

On this page we presented the ACAD Historical PE Ratio information for ACADIA Pharmaceuticals' stock. The average ACAD historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 57.5. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ACAD historical PE based on this TTM earnings result method is 42.1. Note: any PE calculations resulting in a value exceeding 500 were discarded as not meaningful. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ACAD historical PE result, against the recent PE: when this page was posted on 6/4/2026, the most recent closing price for ACAD had been 21.72, and the most recent quarterly earnings result, annualized, was 0.08. Meanwhile, the most recent TTM earnings summed to 0.58. From these numbers, we calculate the recent ACAD PE on 6/4/2026 based on annualized quarterly EPS was 271.5. Based on ACAD's history, that recent PE is elevated relative to the historical average, with the recent PE 372.2% higher than the historical average PE across our data set for ACADIA Pharmaceuticals. Looking at the recent ACAD PE on 6/4/2026 based on TTM EPS, we calculate the ratio at 37.4. Based on ACAD's history, that recent PE is low relative to the historical average, with the recent PE 11.2% lower than the average PE across our ACADIA Pharmaceuticals data set with TTM EPS used in the calculation at each period.

Another interesting ACAD historical PE Ratio calculation we look at is to take the median earnings per share of the last four quarters for ACAD, and then annualize the resulting value... with that annualized number then being used in the PE calculation. To walk through this math for ACAD, we start with the past four EPS numbers and we first sort them from lowest to highest: 0.02, 0.14, 0.16, and 0.26. We then toss out the highest and lowest result, and then take the average of those two middle numbers — 0.14 and 0.16 — which gives us the median of 0.15. Basically the way to think about this 0.15 number is this: for the trailing four earnings reports, 0.15 marks the "middle ground" number where ACAD has reported a value higher than 0.15 half the time, and has reported a value lower than 0.15 half the time. Annualizing that median value then gets us to 0.6/share, which we use as the denominator in our next PE calculation. With 21.72 as the numerator (as of 6/4/2026), the calculation is then 21.72 / 0.6 = 36.2 as the ACAD PE ratio as of 6/4/2026, based on that annualized median value we calculated.

For self directed investors doing their due diligence on ACAD or any other given stock, valuation analysis for ACAD can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate ACADIA Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ACAD. Thanks for visiting, and the next time you need to research ACAD Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.